Spots Global Cancer Trial Database for metastatic non small cell lung cancer
Every month we try and update this database with for metastatic non small cell lung cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | NCT04511533 | Metastatic Non ... | Dacomitinib | 18 Years - | Pfizer | |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05429320 | Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ... | Local ablative ... Blood collectio... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | NCT03497767 | Metastatic Non ... | Osimertinib Stereotactic Ra... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment | NCT05167500 | Metastatic Non ... | Lorlatinib | 18 Years - | Fundación GECP | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC | NCT06068153 | Metastatic Non ... KRAS G12C | Sotorasib Lenvatinib | 18 Years - | ETOP IBCSG Partners Foundation | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | NCT04511533 | Metastatic Non ... | Dacomitinib | 18 Years - | Pfizer | |
| A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases | NCT03497767 | Metastatic Non ... | Osimertinib Stereotactic Ra... | 18 Years - | Trans Tasman Radiation Oncology Group | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC | NCT05236608 | Metastatic Non ... | Nivolumab ADG106 | 21 Years - 99 Years | National University Hospital, Singapore | |
| Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer | NCT00510445 | Lung Cancer | Imetelstat Sodi... | 18 Years - | Geron Corporation | |
| Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy | NCT02705820 | Metastatic Non ... | Pembrolizumab | 18 Years - | Bank of Cyprus Oncology Centre | |
| Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC | NCT05278052 | Oligometastatic... Metastatic Non ... | Local consolida... Standard mainte... | 18 Years - 99 Years | Tata Memorial Hospital | |
| C-TIL051 in Non-Small Cell Lung Cancer | NCT05676749 | Metastatic Non ... | C-TIL051 | 18 Years - | AbelZeta, Inc. | |
| Datopotamab (DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer | NCT04940325 | Metastatic Lung... | DS-1062a | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | NCT04965090 | Metastatic Non ... Recurrent Non S... | Amivantamab Lazertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) | NCT05429320 | Non-small Cell ... Metastatic Non ... Nsclc NSCLC Stage IV Minimal Residua... Non Small Cell ... | Local ablative ... Blood collectio... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT04743505 | Metastatic Non ... | APL-101 Osimertinib | 18 Years - | Washington University School of Medicine | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Medical Access Program for Datopotamab Deruxtecan in NSCLC Patients | NCT06279728 | Advanced Non-Sm... Metastatic Non ... | Datopotamab der... | 18 Years - | Daiichi Sankyo | |
| C-TIL051 in Non-Small Cell Lung Cancer | NCT05676749 | Metastatic Non ... | C-TIL051 | 18 Years - | AbelZeta, Inc. | |
| Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) | NCT04884282 | Metastatic Non ... | Tedopi Nivolumab Docetaxel | 18 Years - | Fondazione Ricerca Traslazionale | |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | NCT05478538 | Non Small Cell ... Metastatic Non ... NSCLC Metastatic NSCL... | Core Needle or ... | 18 Years - | Elephas | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | NCT06066138 | Locally Advance... Metastatic Alve... Locally Advance... Metastatic Non ... Locally Advance... Metastatic Smal... Locally Advance... Metastatic Hepa... Locally Advance... Metastatic Mela... | Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | NCT05215340 | Metastatic Non ... | Datopotamab Der... Pembrolizumab | 18 Years - | Daiichi Sankyo | |
| CISH Inactivated TILs in the Treatment of NSCLC | NCT05566223 | Carcinoma, Non-... Metastatic Non ... Stage IV Non-sm... Squamous Cell L... Adenocarcinoma ... Large Cell Lung... | Fludarabine Cyclophosphamid... CISH Inactivate... Aldesleukin Pembrolizumab | 18 Years - 75 Years | Intima Bioscience, Inc. | |
| A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC) | NCT04965090 | Metastatic Non ... Recurrent Non S... | Amivantamab Lazertinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | NCT06060613 | Tumor Skin Metastatic Mela... Melanoma Lung Cancer Metastatic Lung... Non Small Cell ... Metastatic Non ... | OBX-115 | 18 Years - | Obsidian Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
